Alamar Biosciences, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Alamar reported Q3 2026 revenue of $33.5M (+68% YoY), with gross margin expanding to 61.5% from 59.7%. The company raised full-year 2026 revenue guidance to $121–123M (64% growth midpoint) from prior guidance of $116–120M. Key wins include UK Biobank selection for 80,000-sample Parkinson's/Alzheimer's study and GSK collaboration for 60,000-sample respiratory/liver/kidney/neurological/autoimmune study. President Tod White, who joined in March 2021 and was promoted in October 2025, will retire at year-end 2026 but continue as advisor through June 2027.
Why this rating
Revenue guidance raise of ~$2.5M midpoint (~2% of total assets) is modest. However, 68% YoY Q3 growth, margin expansion, major pharma partnerships (GSK), and biobank collaborations signal strong momentum. Leadership transition is orderly. Strong cash position ($231.5M, 59% of assets) supports growth trajectory. Material but not transformational relative to company scale.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.